Page last updated: 2024-09-05

senicapoc and Anemia, Sickle Cell

senicapoc has been researched along with Anemia, Sickle Cell in 16 studies

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (50.00)29.6817
2010's7 (43.75)24.3611
2020's1 (6.25)2.80

Authors

AuthorsStudies
Beuzard, Y; Brugnara, C; Corrocher, R; De Franceschi, L; McNaughton-Smith, GA; Stocker, JW1
Arrington, S; Burns, JF; Creech, C; de Franceschi, L; McNaughton-Smith, GA; Rigdon, GC; Shelton, T; Stocker, JW1
Ataga, KI; Brugnara, C; Staffa, SJ; Stocker, JW1
Ballas, SK; Nagalla, S4
Ataga, KI; Stocker, J1
Ataga, KI; Ballas, SK; Bigelow, C; Galacteros, F; Hull, JH; James, LS; Kutlar, A; Reid, M; Smith, WR; Stocker, JW; Yasin, Z1
Kato, GJ; Mendelsohn, L; Minniti, CP; Remaley, AT; Rigdon, GC; Stocker, JW; Wilson, J1
Castro, OL; Gladwin, MT; Gordeuk, VR; Steinberg, MH1
Okpala, IE1
Aliyu, ZY; Kato, GJ; Tumblin, AR1
Okpala, I1
Ataga, KI; Davis, GA; Desimone, PA; Orringer, EP; Stocker, JW; Styles, L; Swerdlow, P; Vichinsky, EP1
Ataga, KI; Castro, O; De Castro, LM; Kutlar, A; Orringer, EP; Rigdon, GC; Saunthararajah, Y; Smith, WR; Stocker, JW; Swerdlow, P; Vichinsky, E1

Reviews

7 review(s) available for senicapoc and Anemia, Sickle Cell

ArticleYear
Drugs for preventing red blood cell dehydration in people with sickle cell disease.
    The Cochrane database of systematic reviews, 2018, 10-19, Volume: 10

    Topics: Acetamides; Anemia, Sickle Cell; Antisickling Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dehydration; Early Termination of Clinical Trials; Erythrocyte Aging; Erythrocytes; Humans; Piracetam; Quality of Life; Randomized Controlled Trials as Topic; Trityl Compounds; Zinc Sulfate

2018
Drugs for preventing red blood cell dehydration in people with sickle cell disease.
    The Cochrane database of systematic reviews, 2016, Mar-04, Volume: 3

    Topics: Acetamides; Anemia, Sickle Cell; Antisickling Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dehydration; Early Termination of Clinical Trials; Erythrocyte Aging; Erythrocytes; Humans; Piracetam; Randomized Controlled Trials as Topic; Trityl Compounds; Zinc Sulfate

2016
Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.
    Expert opinion on investigational drugs, 2009, Volume: 18, Issue:2

    Topics: Acetamides; Anemia, Sickle Cell; Animals; Animals, Genetically Modified; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Hemolysis; Humans; Mice; Trityl Compounds

2009
Drugs for preventing red blood cell dehydration in people with sickle cell disease.
    The Cochrane database of systematic reviews, 2010, Jan-20, Issue:1

    Topics: Acetamides; Anemia, Sickle Cell; Antisickling Agents; Dehydration; Erythrocyte Aging; Erythrocytes; Humans; Randomized Controlled Trials as Topic; Trityl Compounds; Zinc Sulfate

2010
Drugs for preventing red blood cell dehydration in people with sickle cell disease.
    The Cochrane database of systematic reviews, 2012, Jul-11, Issue:7

    Topics: Acetamides; Anemia, Sickle Cell; Antisickling Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dehydration; Early Termination of Clinical Trials; Erythrocyte Aging; Erythrocytes; Humans; Piracetam; Randomized Controlled Trials as Topic; Trityl Compounds; Zinc Sulfate

2012
New therapies for sickle cell disease.
    Hematology/oncology clinics of North America, 2005, Volume: 19, Issue:5

    Topics: Acetamides; Anemia, Sickle Cell; Calcium Channel Blockers; Cell Adhesion; Fatty Acids, Omega-3; Humans; Hydroxyurea; Hypertension, Pulmonary; Iron Overload; Stroke; Trityl Compounds

2005
Investigational agents for sickle cell disease.
    Expert opinion on investigational drugs, 2006, Volume: 15, Issue:8

    Topics: Acetamides; Anemia, Sickle Cell; Animals; Antihypertensive Agents; Antisickling Agents; Benzaldehydes; Benzoates; Carnitine; Cell Adhesion; Deferasirox; Endothelium, Vascular; Etilefrine; Female; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Hypertension, Pulmonary; Iron Chelating Agents; Male; Membrane Glycoproteins; Potassium Channels, Calcium-Activated; Priapism; Recombinant Fusion Proteins; Triazoles; Trityl Compounds; Vasoconstrictor Agents

2006

Trials

3 trial(s) available for senicapoc and Anemia, Sickle Cell

ArticleYear
Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapo
    British journal of haematology, 2011, Volume: 153, Issue:1

    Topics: Acetamides; Adolescent; Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Double-Blind Method; Drug Administration Schedule; Erythrocyte Aging; Female; Hematocrit; Hemolysis; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; Male; Middle Aged; Pain; Treatment Outcome; Trityl Compounds; Young Adult

2011
Dose-escalation study of ICA-17043 in patients with sickle cell disease.
    Pharmacotherapy, 2006, Volume: 26, Issue:11

    Topics: Acetamides; Adult; Anemia, Sickle Cell; Double-Blind Method; Humans; Middle Aged; Potassium Channels, Calcium-Activated; Trityl Compounds

2006
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.
    Blood, 2008, Apr-15, Volume: 111, Issue:8

    Topics: Acetamides; Adolescent; Adult; Anemia, Sickle Cell; Female; Humans; Male; Middle Aged; Potassium Channel Blockers; Time Factors; Treatment Outcome; Trityl Compounds

2008

Other Studies

6 other study(ies) available for senicapoc and Anemia, Sickle Cell

ArticleYear
ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice.
    Blood, 2003, Mar-15, Volume: 101, Issue:6

    Topics: Acetamides; Anemia, Sickle Cell; Animals; Calcium; Calcium Channel Blockers; Clotrimazole; Erythrocytes; Female; Humans; Hypoxia; Male; Mice; Mice, Transgenic; Potassium Channels, Calcium-Activated; Rubidium; Trityl Compounds

2003
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
    Journal of medicinal chemistry, 2008, Feb-28, Volume: 51, Issue:4

    Topics: Acetamides; Anemia, Sickle Cell; Animals; Biological Availability; Clotrimazole; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; Male; Mice; Potassium Channel Blockers; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Trityl Compounds

2008
Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial.
    British journal of haematology, 2021, Volume: 192, Issue:5

    Topics: Acetamides; Anemia, Sickle Cell; Benzaldehydes; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hemoglobins; Hemolysis; Humans; Hydroxyurea; Intermediate-Conductance Calcium-Activated Potassium Channels; Pyrazines; Pyrazoles; Trityl Compounds

2021
Anti-haemolytic effect of senicapoc and decrease in NT-proBNP in adults with sickle cell anaemia.
    British journal of haematology, 2011, Volume: 155, Issue:5

    Topics: Acetamides; Adult; Anemia, Sickle Cell; Female; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Trityl Compounds

2011
Senicapoc trial results support the existence of different sub-phenotypes of sickle cell disease with possible drug-induced phenotypic shifts.
    British journal of haematology, 2011, Volume: 155, Issue:5

    Topics: Acetamides; Anemia, Sickle Cell; Hemoglobin, Sickle; Humans; Pain; Phenotype; Randomized Controlled Trials as Topic; Trityl Compounds

2011
Current therapy of sickle cell disease.
    Haematologica, 2006, Volume: 91, Issue:1

    Topics: Acetamides; Anemia, Sickle Cell; Azacitidine; Butyrates; Decitabine; Erythrocyte Transfusion; Humans; Hydroxyurea; Nitric Oxide; Trityl Compounds

2006
chemdatabank.com